title: Evaluation of the efficacy and safety of switching to tenofovir, emtricitabine, and rilpivirine in treatment-experienced patients.
authors.affiliation: *Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, Assistance Publique -Hôpitaux de Paris, Paris, France †Université Paris 6 Pierre et Marie Curie, Paris, France ‡Unité de Virologie, AP-HP, Hôpital Saint-Antoine, Paris, France §INSERM, UMR_S 1136, Institut Pierre Louis d¹Epidémiologie et de Santé Publique, Paris, France.
authors.forename: Laure
authors.initials: L
authors.lastname: Surgers
authors.forename: Nadia
authors.initials: N
authors.lastname: Valin
authors.forename: Céline
authors.initials: C
authors.lastname: Viala
authors.forename: Anders
authors.initials: A
authors.lastname: Boyd
authors.forename: Laurent
authors.initials: L
authors.lastname: Fonquernie
authors.forename: Pierre-Marie
authors.initials: PM
authors.lastname: Girard
authors.forename: Laurence
authors.initials: L
authors.lastname: Morand-Joubert
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Meynard
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004359:Drug Therapy, Combination; D000068679:Emtricitabine; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles / Q000008:administration & dosage; D063065:Organophosphonates / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D000068696:Rilpivirine; D000068698:Tenofovir; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D009570:Nitriles; D063065:Organophosphonates; D011743:Pyrimidines; D003841:Deoxycytidine; D000068698:Tenofovir; D000068696:Rilpivirine; D000068679:Emtricitabine; D000225:Adenine